Sanofi to launch HIB shot in Japan

Sanofi Pasteur says it's poised to enter the Japanese market with its ActHIB vaccine that targets Haemophilius influenza type b; the shot will be marketed there by Daiichi-Sankyo and will be available beginning next month. Report

Suggested Articles

Pfizer’s Ibrance has met with success in breast cancer since breaking onto the scene in 2015. But its first foray into early breast cancer was a bust.

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.